Inmed's inm-901 significantly reduces neuroinflammation in alzheimer's disease ex vivo study

Demonstrates statistically significant reduction of pro-inflammatory cytokines, including il-6, il-1Β, il-2, and kc/gro significantly reduces levels of inflammasome marker, nlrp3, a key contributor to neurodegeneration reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology vancouver, british columbia--(newsfile corp. - june 24, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that inm-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in alzheimer's disease. the study evaluated inm-901 in an ex vivo model of lipopolysaccharide (lps)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines il-6, il-1Β, il-2, and kc/gro and inflammasome marker nlrp3.
INM Ratings Summary
INM Quant Ranking